Acura Pharmaceuticals, Inc.
ACUR
$0.01
$0.0072257.14%
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -44.87% | -52.17% | -15.16% | 34.36% | 171.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.87% | -52.17% | -15.16% | 34.36% | 171.47% |
| Cost of Revenue | -11.34% | -1.02% | 13.93% | 18.34% | 61.71% |
| Gross Profit | -71.85% | -80.12% | -37.01% | 55.30% | 498.41% |
| SG&A Expenses | -10.43% | -12.51% | -10.92% | 0.11% | 19.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.87% | -7.18% | 0.17% | 8.22% | 36.90% |
| Operating Income | -457.42% | -196.29% | -394.41% | 87.59% | 124.84% |
| Income Before Tax | -42.10% | -2,404.41% | 75.65% | 67.99% | 79.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.10% | -2,404.41% | 75.65% | 67.99% | 79.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.10% | -2,404.41% | 75.65% | 67.99% | 79.34% |
| EBIT | -457.42% | -196.29% | -394.41% | 87.59% | 124.84% |
| EBITDA | -314.08% | -175.78% | -183.09% | 107.74% | 149.64% |
| EPS Basic | -12.00% | -2,078.26% | 83.13% | 79.02% | 86.32% |
| Normalized Basic EPS | -657.69% | -295.86% | -32.28% | 71.89% | 94.65% |
| EPS Diluted | -25.94% | -7,385.71% | 80.51% | 77.15% | 85.77% |
| Normalized Diluted EPS | -629.63% | -297.22% | -33.07% | 71.62% | 94.44% |
| Average Basic Shares Outstanding | 42.45% | 9.49% | 10.20% | 21.15% | 33.69% |
| Average Diluted Shares Outstanding | 42.25% | 9.33% | 10.35% | 21.31% | 33.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
